• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thymoma Associated Myasthenia Gravis Successfully Treated With Ravulizumab.

作者信息

Zouvelou Vasiliki, Tatouli Ioanna, Lymperopoulos Loukas, Strataki Eleni, Tzavella Dimitra, Vourlakou Christina, Zisis Charalampos, Kontogiannis Sofoklis

机构信息

1st Neurology Department, National and Kapodistrian University of Athens, Greece Eginitio Hospital, ERN EURO-MND, Athens, Greece.

Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Muscle Nerve. 2025 Feb;71(2):275-277. doi: 10.1002/mus.28320. Epub 2024 Dec 12.

DOI:10.1002/mus.28320
PMID:39668649
Abstract
摘要

相似文献

1
Thymoma Associated Myasthenia Gravis Successfully Treated With Ravulizumab.用ravulizumab成功治疗胸腺瘤相关重症肌无力
Muscle Nerve. 2025 Feb;71(2):275-277. doi: 10.1002/mus.28320. Epub 2024 Dec 12.
2
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.诊断后时间对瑞夫利珠单抗治疗全身性重症肌无力患者疗效的影响：CHAMPION MG 研究的事后亚组分析。
Muscle Nerve. 2024 May;69(5):556-565. doi: 10.1002/mus.28044. Epub 2024 Feb 21.
3
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.评估ravulizumab或efgartigimod对重症肌无力症状的控制：两种不同治疗方法的患者体验评估
Curr Med Res Opin. 2025 May;41(5):817-827. doi: 10.1080/03007995.2025.2497906. Epub 2025 May 24.
4
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.ravulizumab治疗抗乙酰胆碱受体抗体阳性全身型重症肌无力成人患者的长期疗效和安全性：3期CHAMPION MG开放标签扩展研究的最终结果
Eur J Neurol. 2025 Apr;32(4):e70158. doi: 10.1111/ene.70158.
5
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.抗乙酰胆碱受体抗体阳性全身型重症肌无力成人患者使用拉那利尤单抗的长期疗效和安全性：III 期 CHAMPION MG 开放标签扩展研究结果。
J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27.
6
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.依酚氯胺和瑞昔芦单抗治疗乙酰胆碱受体抗体阳性（AChR-Ab+）全身型重症肌无力：间接治疗比较。
Adv Ther. 2024 Jun;41(6):2486-2499. doi: 10.1007/s12325-024-02856-3. Epub 2024 Apr 20.
7
Successful Control of Myasthenic Crisis After the Introduction of Ravulizumab in Myasthenia Gravis: A Case Report.在重症肌无力患者中引入ravulizumab后成功控制重症肌无力危象：一例报告
Cureus. 2024 Nov 20;16(11):e74117. doi: 10.7759/cureus.74117. eCollection 2024 Nov.
8
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.研究总结：终末补体抑制剂ravulizumab治疗全身型重症肌无力
Neurol Ther. 2023 Oct;12(5):1435-1438. doi: 10.1007/s40120-023-00514-4. Epub 2023 Jun 23.
9
Surgery of myasthenia gravis associated or not with thymoma: a retrospective study of 43 cases.重症肌无力合并或不合并胸腺瘤的手术治疗：43 例回顾性研究。
Heart Lung Circ. 2013 Sep;22(9):738-41. doi: 10.1016/j.hlc.2013.02.010. Epub 2013 Mar 30.
10
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.瑞昔珠单抗治疗全身性重症肌无力。
NEJM Evid. 2022 May;1(5):EVIDoa2100066. doi: 10.1056/EVIDoa2100066. Epub 2022 Apr 26.

引用本文的文献

1
Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.ravulizumab治疗全身型重症肌无力：一项多中心真实世界经验
J Neurol. 2025 May 14;272(6):396. doi: 10.1007/s00415-025-13127-8.